Status:
COMPLETED
Epi-On Corneal Crosslinking for Keratoconus
Lead Sponsor:
Comprehensive EyeCare of Central Ohio
Collaborating Sponsors:
Glaukos Corporation
Conditions:
Keratoconus
Keratoconus, Unstable
Eligibility:
All Genders
14-40 years
Phase:
PHASE4
Brief Summary
Epithelium-On Corneal Crosslinking for Keratoconus.
Detailed Description
Subjects with a diagnosis of progressive keratoconus will be evaluated for suitability as a candidate for Corneal Crosslinking (CXL). Subjects that as candidates for CXL will be asked to participate i...
Eligibility Criteria
Inclusion
- 12 to 40 years of age, having a diagnosis of keratoconus, signed written informed consent, willingness and ability to comply with schedule for follow-up visits
Exclusion
- Previous ocular condition (other than refractive error) in the eye(s) to be treated that may predispose the eye for future complications (herpes simplex/zoster, recurrent corneal erosion syndrome, corneal melt, corneal dystrophy, etc.) Pregnancy, intent to become pregnant, or lactation during study. Corneal pachymetry \<350 microns at the thinnest point measured by Pentacam in the eye(s) to be treated.
- Nystagmus or any other condition that would prevent steady gaze. Other systemic condition that in the investigator's opinion would not allow the patient to be a good candidate for the study.
Key Trial Info
Start Date :
July 18 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2019
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03245853
Start Date
July 18 2017
End Date
September 30 2019
Last Update
January 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Comprehensive EyeCare of Central Ohio
Westerville, Ohio, United States, 43082